Phase I Evaluation of Pharmacokinetics, Safety, and Tolerability of Repeated Topical PARENTIDE Application in Healthy Volunteers

The primary objective of this Phase I clinical trial is to evaluate the **pharmacokinetics**, safety, and tolerability of repeated topical application of PARENTIDE in healthy volunteers. This assessment is clinically relevant as it provides foundational data on the absorption, distribution, metabolism, and excretion of the compound, as well as its safety profile, which are critical for determining the feasibility of further clinical development. No secondary objectives are specified for this study.

The clinical trial involves **healthy volunteers** as the study population, encompassing both male and female participants. The age range of the participants falls within categories 3 and 4, which typically correspond to adults and older adults. The trial does not include a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants were selected based on their general health status, ensuring they are free from significant medical conditions. Lifestyle considerations such as diet, physical activity, and habits were not specified. The sponsor did not provide specific inclusion or exclusion criteria for this study.

The clinical trial is designed as a **Phase I** study to evaluate the pharmacokinetics, safety, and tolerability of repeated topical application of a compound in **healthy volunteers**. The trial employs a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The estimated duration of the trial spans from January 15, 2025, to March 15, 2025, encompassing a recruitment period and subsequent study phases.

Participants will undergo a sequence of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a comprehensive evaluation to confirm the health status of the volunteers. Following successful screening, participants will be randomized into different study arms. Throughout the trial, follow-up visits will be scheduled at regular intervals to monitor the participants' response to the treatment, assess any adverse events, and ensure adherence to the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather data on the primary and secondary endpoints.

The expected length of participant involvement is approximately two months, contingent upon adherence to the study protocol and absence of any adverse events that may necessitate early termination. Conditions that could lead to early withdrawal from the study include significant adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is structured to maintain the highest ethical standards and ensure the safety and well-being of all participants throughout its duration.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to begin recruitment on January 15, 2025, with an estimated end date of March 15, 2025. Efficacy will be evaluated using specific parameters or endpoints, although these are not detailed in the provided data. The trial will follow a structured methodology to measure, collect, and analyze these efficacy parameters, adhering to the standards expected in a Phase 3 clinical trial. The trial's design and execution will ensure that the efficacy assessments are conducted systematically and objectively, in line with clinical trial protocols.